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1  | INTRODUC TION
RNA interference (RNAi) is an important defence-response system of 
eukaryotic cells that results in the silencing of viral gene transcripts 
(Ratcliff et al., 1997; Fire et al., 1998). In the process, small interfering 
RNAs (siRNAs) play a crucial role in amplification and maintenance 
of the silencing response through loading onto Argonaute proteins, 
which uses siRNAs to target and cleave homologous viral RNAs (Chiu 
and Rana, 2003). As such, RNAi has become a powerful research 
tool for studies of gene function and siRNA-based antiviral therapies 
(Tuschl and Borkhardt, 2002; Small, 2007; Badia et al., 2017; Ghosh 
et al., 2017; Qureshi et al., 2018).
Viruses  are some of the most damaging pathogens in sweet po-
tato, and more than 30 viruses in nine families have been reported 
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Abstract
The class 1 ribonuclease III (RNase III) encoded by Sweet potato chlorotic stunt virus 
(CSR3) suppresses RNA silencing in plant cells and thereby counters the host antiviral 
response by cleaving host small interfering RNAs, which are indispensable compo-
nents of the plant RNA interference (RNAi) pathway. The synergy between sweet 
potato chlorotic stunt virus and sweet potato feathery mottle virus can reduce crop 
yields by 90%. Inhibitors of CSR3 might prove efficacious to counter this viral threat, 
yet no screen has been carried out to identify such inhibitors. Here, we report a 
novel high-throughput screening (HTS) assay based on fluorescence resonance en-
ergy transfer (FRET) for identifying inhibitors of CSR3. For monitoring CSR3 activity 
via HTS, we used a small interfering RNA substrate that was labelled with a FRET-
compatible dye. The optimized HTS assay yielded 109 potential inhibitors of CSR3 
out of 6,620 compounds tested from different small-molecule libraries. The three 
best inhibitor candidates were validated with a dose–response assay. In addition, a 
parallel screen of the selected candidates was carried out for a similar class 1 RNase 
III enzyme from Escherichia coli (EcR3), and this screen yielded a different set of in-
hibitors. Thus, our results show that the CSR3 and EcR3 enzymes were inhibited by 
distinct types of molecules, indicating that this HTS assay could be widely applied in 
drug discovery of class 1 RNase III enzymes.
K E Y W O R D S
fluorescence resonance energy transfer, high-throughput screening, RNA silencing 
suppressor, RNase III, small interfering RNA
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to infect the crop. Among them, the crinivirus sweet potato chlo-
rotic stunt virus (SPCSV) is one of the most harmful viruses be-
cause of its key role in synergistic infections (Clark et al., 2012; 
Valkonen et al., 2015). Studies have shown that SPCSV can build 
synergistic interactions with RNA viruses (potyviruses, ipomovi-
ruses, carlaviruses, and cucumoviruses) as well as DNA viruses 
(cavemoviruses, begomoviruses, and solendoviruses), increasing 
plant susceptibility to those viruses and causing severe symptoms 
(Mukasa et al., 2006; Untiveros et al., 2007; Kreuze et al., 2008; 
Cuellar et al., 2011, 2015). Among them, the disease caused by the 
synergistic interaction of SPCSV and the potyvirus sweet potato 
feathery mottle virus (SPFMV) is the most common and devas-
tating disease in sweet potato (Gutierrez et al., 2003; Tairo et al., 
2005; Clark et al., 2012). Furthermore, it has been proved that the 
synergistic interaction was mediated by a class 1 RNase III protein 
encoded by the RNA1 genome segment of SPCSV (abbreviated as 
CSR3 in this study), and its endonuclease function was necessary 
for its role as an RNA silencing suppressor in inducing synergistic 
disease (Kreuze et al., 2005; Cuellar et al., 2009; Weinheimer et al., 
2015). Therefore, considering the key role of CSR3, identification 
of CSR3 inhibitors could be an effective strategy to defend against 
synergistic virus disease in sweet potato.
Enzymes of the ribonuclease III (RNase III) family are expressed 
in a variety of organisms including bacteria and multicellular eukary-
otes, with their enzyme size ranging from 140 to 1,900 amino acid 
residues (Court et al., 2013). Among them, RNase III of SPCSV (CSR3) 
can cleave siRNAs, leading to the suppression of the RNA silencing 
pathway in sweet potato (Kreuze et al., 2005). In addition, in viruses, 
another RNase III with similar function has only been found in the 
animal virus Pike-perch iridovirus up to now (Weinheimer et al., 2015). 
Studies have demonstrated that CSR3 sequences are highly con-
served in SPCSV that infect wild species of sweet potato, indicating 
that CSR3-mediated host RNAi suppression is a conserved function 
that is necessary for infectivity (Tugume et al., 2013). Despite the 
important role of CSR3 in suppressing the host RNA silencing, no 
inhibitors for RNase III of SPCSV and Pike-perch iridovirus have been 
reported, and no inhibitor screen has been applied for RNase III fam-
ily enzymes according to the Binding Database (https://www.bindi 
ngdb.org/bind/index.jsp) or Web of Science (https://apps.webof 
knowl edge.com). At present, several viral RNA silencing suppressors 
(RSSs) have been reported in plants, such as P19 of tombusviruses, 
HcPro of potyviruses, 2b of cucumoviruses, and P15 of pecluviruses, 
which interfere with different components of the RNA silencing 
pathway (Moissiard and Voinnet, 2004; Burgyan and Havelda, 2011). 
However, chemical inhibitor screening has been mainly carried 
out with proteins P19 and 2b, for example the screening of 5,000 
chemicals for their ability to prevent siRNA binding to viral RSS of 
cucumber mosaic virus (CMV) (2b) and tomato bushy stunt virus 
(TBSV) (p19) led to the identification of strong inhibitors (Shimura 
et al., 2008). Interestingly, this screening led to the identification of 
efficient antiviral agents against turnip mosaic virus (TuMV) later on 
(Fujiwara et al., 2013). Inhibitor screening for the RSS was mainly 
carried out by methods such as surface plasmon resonance and 
electrophoretic mobility shift assay (Sagan et al., 2007; Danielson 
et al., 2015; Hu et al., 2018).
Fluorescence resonance energy transfer (FRET), which is the 
nonradioactive transfer of energy between two molecules, has 
been used for studies of protein–protein interactions as well as 
high-throughput screening (HTS) assays for drug discovery (Boute 
et al., 2002; Benz et al., 2011). FRET-based assays are suitable for 
HTS because the method is sensitive and compatible with small 
volumes (Klostermeier et al., 2004). FRET has also been used as a 
probe for tracking the stability, formation, delivery, and degrada-
tion of siRNAs in gene-silencing studies by spectral imaging and 
a fluorescence detection system (Jarve et al., 2007; Alabi et al., 
2012).
An effective HTS assay is necessary for screening libraries of 
compounds to identify candidate inhibitors of enzyme activities 
(Macarron et al., 2011). Therefore, we developed a cost-effective, 
FRET-based HTS assay for identifying inhibitors of CSR3 using 
siRNA as the substrate. The coefficient Z prime (Z′), measuring sta-
tistical effect size as defined by Zhang et al. (1999), was employed to 
evaluate the suitability of the HTS assay by taking into account infor-
mation from dynamic range and variation of signal measurements. 
Moreover, the decrease in reaction rate was defined in terms of 
the percentage of inhibition (PI) (Schultz, 2006). We used an siRNA 
tagged with a fluorescein reporter and a quencher as the substrate 
to measure the PI of compounds. Finally, our success with identify-
ing CSR3 inhibitors with this HTS assay and its successful application 
on RNase III of Escherichia coli (EcR3) suggests that the HTS can be 
used for screening inhibitors of other CSR3-like enzymes.
2  | RESULTS
2.1 | CSR3 characteristics
Enzymes of high activity are necessary for the success of any HTS 
assay. For the development of our HTS assay, His-tagged CSR3 and 
its double-mutant CSR3-A (D37A, D44A) were expressed in E. coli 
and purified with Ni-NTA agarose. The recombinant CSR3 and its 
mutant were analysed with sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis (SDS-PAGE), revealing a predominant band 
at c.26 kDa (Figure 1a). A second round of elution (Figure 1a) yielded 
the majority of CSR3, and aliquots of this fraction were made. In 
addition, western blotting showed that both proteins can exist as 
mixed monomer, dimer, and tetramer in storage buffer (Figure 1b). 
We also characterized the oligomerization of CSR3 by size-exclusion 
chromatography with detection using multi-angle light scattering. 
The only detectable protein peak at molecular mass 68.93 kDa was 
larger than that of the theoretical dimer of molecular mass 52 kDa, 
which could be explained either because most of our CSR3 prepa-
ration comprised a mixture of dimers and tetramers in phosphate-
buffered saline (PBS) running buffer, or by the nonspherical nature 
of the dimer, which could cause a disruption during size-exclusion 
elution (Figure 1c). In general, the molecule state of CSR3 was 
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consistent with previous characterization of CSR3 by native west-
ern blotting (Weinheimer et al., 2014) and with functional and struc-
tural studies of another class 1 RNase III from Aquifex aeolicus, which 
demonstrated that the dimer is the catalytically active form of class 
1 RNase III enzymes (Blaszczyk et al., 2001). The CSR3 activity was 
evaluated using a 200-bp double-stranded RNA (dsRNA) substrate. 
This substrate was cleaved to smaller dsRNA fragments in the pres-
ence of CSR3 (Figure 1d) but remained intact in the presence of 
CSR3-A, as was also the case for the control reaction lacking any 
endoribonuclease (Ctl). These results validated the activity of the 
purified CSR3 enzyme.
2.2 | FRET assay setup
Our HTS assay was based on FRET, in which CSR3 cleaves a labelled 
siRNA and generates a fluorescent signal (Figure 2a,b). Specifically, 
a two-nucleotide overhang of a 22-bp siRNA was labelled with a 
fluorophore reporter (FAM) and a quencher (HBQ1) at the 5′ and 3′ 
ends, respectively, of the sense-strand. Fluorescence was acquired 
with excitation/emission of 485/520 nm, reflecting the unquenched 
fluorescence intensity of the reporter. Two reaction conditions 
were used for the negative and positive controls to normalize CSR3-
inhibition data acquired for all compounds. For the negative control, 
cleavage of the labelled siRNA by CSR3 disrupts the energy trans-
fer from the donor to the receptor and hence loss of FRET quench-
ing, allowing us to detect the fluorescence emission of the reporter 
(Figure 2a). For the positive control (or blank control), the reaction 
was carried out either with the catalytically inactive CSR3-A or in 
the absence of any added enzyme, so that labelled siRNA integrity 
was maintained and fluorescence emissions from the reporter re-
mained quenched by HBQ1 (Figure 2b). There was a clear increase 
in fluorescence in the absence of FRET (i.e., negative controls), 
whereas fluorescence remained stable over time in the presence of 
FRET (i.e., positive controls) (Figure 2c). As both positive controls 
showed similar trends, in order to keep the HTS process simple no 
F I G U R E  1   Preparation of CSR3 enzymes and characterization of catalytic activity and oligomerization. (a) SDS-polyacrylamide gel 
electrophoresis of the purified CSR3 and CSR3-A. The gel was stained with Coomassie Brilliant Blue; flow-through (Ft), washing steps 1, 
2 (W1, W2), elution 1–4 (E1–E4), protein ladder (L). (b) Western blotting for CSR3 and CSR3-A using a rabbit polyclonal antiserum against 
CSR3. (c) Oligomerization of CSR3 was characterized by size-exclusion chromatography coupled with multi-angle light scattering. The 
calculated molecular mass was 68.93 kDa. (d) Agarose gel (2%) electrophoresis of the dsRNA substrate (200 bp) incubated at 37 °C for 
45 min with CSR3, CSR3-A, or no endoribonuclease (Ctl), DNA ladder (L)
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enzyme condition was applied as the positive control in the follow-
ing optimization and screening assays. Moreover, these two control 
conditions were validated by analysis of the reaction products with 
2% agarose gel electrophoresis (Figure 2d). These results indicate 
that the design of the assay is suitable for HTS.
2.3 | CSR3 titration assay
The rate of increase in fluorescence was dependent on the amount 
of enzyme and labelled siRNA in the reaction. Fluorescence meas-
urements (Figure 3a) showed that, compared with a low concentra-
tion, a high concentration of CSR3 led to a rapid increase and higher 
fluorescence at the beginning of the kinetic measurement. To quan-
tify the increase in fluorescence, we calculated the slopes (fluores-
cence changes over time in seconds depicting the reaction rate of 
CSR3) between all neighbouring detection cycles. The slopes were 
used to select the optimal detection time for each CSR3 concentra-
tion tested. The results suggested that the maximal initial slope for 
the concentrations 144, 72, and 36 nM of CSR3 occurred after 5, 
10, and 14 reaction cycles, respectively (Figure 3b), indicating that 
a lower concentration of enzyme resulted in a longer period dur-
ing which kinetics could be monitored. A very high kinetic rate was 
observed with 288 and 575 nM CSR3 concentrations during the 
first cycle (shown for 288 nM in Figure 3b), making it impossible to 
monitor the reaction at high enzyme concentrations, that is, the la-
belled siRNA was cleaved before fluorescence could be monitored. 
Furthermore, maximal slopes were linearly correlated with CSR3 
concentration (Figure 3c), indicating that the initial velocity of the 
reaction correlated positively with CSR3 concentration with a fixed 
concentration of substrate. The Z′ values with five concentrations 
and three replicates (Table 1) suggested that an enzyme concentra-
tion ranging from 72 to 144 nM could be used because the resulting 
Z′ values were >0.9. Therefore, the final concentration of enzyme 
100 nM CSR3 and substrate 375 nM siRNA were used in HTS assay. 
Moreover, these two control conditions indicated that both the la-
belled siRNA and enzyme were stable at room temperature (25 °C), 
an important aspect for HTS given that 20 assay plates were re-
quired for our screening and each of them has to be run with 12 
detection cycles.
F I G U R E  2   Overview of the fluorescence resonance energy transfer (FRET)-based assay with CSR3 and CSR3-A. Schematic 
representation of the FRET-based assay. The labelled small interfering RNA (siRNA) was incubated with CSR3 (a FRET-absent condition) 
or with either CSR3-A or no enzyme (b FRET-present condition). (c) A representation of fluorescence signal curve of the FRET-absent and 
FRET-present conditions, indicating by real-time relative fluorescence units (RFU) in function of c.17 min total (12 cycles), measured at 37 °C 
by an optic module with excitation at 485 ± 6 nm and detection at 520 ± 5 nm. Data represent the mean ± SD (n = 24). (d) Agarose gel (2%) 
electrophoresis of labelled siRNA incubated for 30 min at 37 °C with CSR3, CSR3-A, or without any enzyme (Ctl). All reactions contained 
15 µl of 375 nM labelled siRNA. L, DNA ladder
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2.4 | Determination of the Kd value for CSR3
To monitor the kinetics of CSR3 endoribonuclease activity, two-
fold dilutions (yielding 50–800 nM) of the labelled siRNA sub-
strate were tested with 50 nM CSR3. As expected, start points of 
raw fluorescence increased with the FRET-siRNA concentration 
(Figure 4a). Moreover, the slope of the raw fluorescence between all 
neighbouring detection cycles was calculated for all cycle numbers. 
These data revealed that the maximal slope (2.2–17.1) increased 
with both FRET-siRNA concentration (50–800 nM) and reaction 
cycles (2–10) (Figure 4b). Finally, the maximal slope for every la-
belled siRNA concentration was used to determine the catalytic 
rate of CSR3. Using the Michaelis–Menten model, the calculated 
Vmax value was 22.47 and the Km value was 228.92 nM (Figure 4c). 
A similar kinetic study of an endonuclease activity demonstrated 
that FRET-based methods were more sensitive and reproducible 
than gel electrophoresis-based methods using radiolabelled sub-
strates (Ghosh et al., 1994).
2.5 | Whole-plate validation
Homogeneity within and consistency between plates is crucial 
for HTS (Ahsen and Bomer, 2005). To assess these aspects of our 
assay, we used three replicate assay plates containing only positive 
F I G U R E  3   Titration assay with CSR3 and labelled small interfering RNA (siRNA). CSR3 (two-fold dilution 575 to 36 nM, plus 0 nM 
control) and labelled siRNA (375 nM) were used to determine the optimal ratio of enzyme-to-substrate concentrations. Three replicate 
plates (z01, z02, z03) containing labelled siRNA were prepared with a dispenser, and enzyme was added to initiate the reaction. (a) Raw 
fluorescence expressed in RFU as a function of detection cycle. In total, 25 cycles were acquired (38 min total). Data represent the 
mean ± SD (n = 48). (b) Slope between neighbouring cycles obtained from raw fluorescence data (a). The highest CSR3 concentration 
(575 nM) was excluded. Data represent the mean ± SD (n = 48). (c) A linear correlation was found between maximal slopes obtained from 
neighbouring cycles (b) and CSR3 concentration
TA B L E  1   Calculated Z′ values for the five different CSR3 
concentrations used in the three replicates over 12 cycles
CSR3 (nM)
Z′
0 min 40 min 80 min
575 0.42 0.57 −1.76
288 0.89 0.75 0.88
144 0.94 0.95 0.96
72 0.93 0.95 0.94
36 0.64 0.77 0.63
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and negative reactions (Figure 5a). The raw fluorescence consist-
ently increased over the 12 cycles for all three replicates, demon-
strating the cross-plate reproducibility of the assay (Figure 5b). 
Fluorescence between the cleaved and uncleaved reactions could 
be easily distinguished. In the positive control (lacking CSR3), fluo-
rescence remained essentially constant during the 12 cycles. In the 
negative control (containing CSR3), fluorescence increased linearly 
from cycles 4 to 12 and data obtained for this range of cycles were 
used to calculate the slope of the reaction. The slope values for the 
positive- and negative-control reactions of the three replicates dif-
fered significantly (analysis of variance, ANOVA; p < .001; Figure 5c). 
By taking into account means of positive and negative slope values 
and their respective standard deviation, we estimated that Z′ val-
ues were >0.5 (0.77 ± 0.08) for all plates, whereas the signal-to-
background ratio was 9.84 ± 0.75 and the signal-to-noise ratio was 
43.17 ± 8.72 (see equation in section 4.8), indicating that our assay 
was suitable for HTS. To avoid any inaccuracy caused by variation 
between screenings, both negative and positive reactions were in-
volved in each plate.
2.6 | Primary HTS screen and a dose–response 
screen of CSR3
The FRET-based assay was used in a primary screen of 6,620 small 
molecules of diverse structure. Of these 6,620 compounds, 109 
(1.66%) had a PI > 30% (for PI distribution of those 109 compounds, 
see Table 2). The 12 compounds with a PI value >90% had diverse 
structures, and no common scaffold was readily apparent (Figure 6).
A dose–response assay was carried out with the top 109 compounds 
(concentration range 1.25 nM to 50 µM). The data were analysed with 
Breeze software, which generates dose–response curves and calcu-
lates the half-maximal inhibitory concentration (IC50) and drug-sen-
sitivity score (DSS) for every compound. Considering that IC50 alone 
cannot comprehensively evaluate the drug sensitivity of the dose–re-
sponse model in HTS assay, DSS was developed by Yadav et al. (2014) as 
a systematic algorithmic solution that integrated five factors: IC50, the 
slope at IC50, minimum activity level, and top and bottom asymptotes 
of dose–response model. The DSS values ranged from 0 to 19.2. Table 3 
presents data for the top three compounds based on DSS values. The 
F I G U R E  4   Determination of the Kd value for CSR3 and titration of labelled small interfering RNA (siRNA) substrates with 50 nM CSR3. 
(a) Raw fluorescence expressed in RFU as a function of detection cycles. In total, 12 cycles were acquired (c.17 min total). Data represent the 
mean ± SD (n = 24). Positive controls (lacking CSR3) was included for each substrate concentration. (b) Slope between neighbouring cycles 
obtained from raw fluorescence data (a). Data represent the mean ± SD (n = 24). (c) Maximal slope calculated from data obtained for five 
siRNA concentrations. The Kd value for CSR3 was calculated with the three-parameter Michaelis–Menten model (MM.3) using the R package 
dcr, resulting in a Km value of 228.92 nM
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three structures differ (Figure 6, starred compounds). In addition, of the 
12 compounds with PI > 90% in the primary screen, 10 were among the 
top 20 most potent compounds as determined in the dose–response 
screen, indicating that the assay was internally consistent even though a 
single CSR3 concentration was used. Table S1 lists the 109 compounds 
from the dose–response screens for CSR3, including information for 
compound identity, IC50, DSS, and dose–response curves.
2.7 | Screening of potential inhibitors for the EcR3
The aforementioned 109 compounds were screened for their ability 
to inhibit the activity of the EcR3. The concentration of each com-
pound was 10 µM (Z′ = 0.82). To get some idea about how widely the 
HTS method can be used for other class 1 RNase III and the specific-
ity of identified inhibitors, EcR3 was screened with the selected 109 
compounds. Results showed that there was a significant difference 
in PI values between the CSR3 and EcR3 screens (ANOVA, p < .001), 
with mean PI values of 54.4% and 17.1%, respectively (Figure 7). For 
EcR3, 32 of the 109 compounds had PI ≥ 30%; this was expected 
because the 109 compounds were selected based on the CSR3 
screen. The differences in PI values might be explained by differ-
ences in the active sites of the two enzymes, in that one amino acid 
is different between EcR3 and CSR3, which might be critical (amino 
acid sequence alignment and active site, Figure S1a,b, respectively). 
Specifically, the active site of CSR3 comprises four residues, namely 
E40, D44, N126, and E129 (black arrows, Figure S1a). The lone dif-
ference is D114 of EcR3, which corresponds to N126 of CSR3, and 
previous studies have shown that, at this position, aspartic acid (D) is 
prevalent in most RNase III family enzymes (Nicholson, 2014).
3  | DISCUSSION
Several strategies could be applied in plant epidemiology to control 
plant viruses by taking into consideration virus–vector and virus–
host interactions. To combat viral diseases such as sweet potato 
virus disease, the most common and effective strategy to date has 
F I G U R E  5   Whole-plate assay to determine the homogeneity and consistency between plates for high-throughput screening. (a) Whole-
plate layout, in which positive controls reflect the absence of fluorescence resonance energy transfer (FRET) (substrate cleaved) and 
negative controls reflect the presence of FRET (substrate not cleaved). (b) Raw fluorescence expressed in RFU as a function of detection 
cycle number reveals an obvious difference in fluorescence between the positive and negative controls. The test was carried out three times 
(z01, z02, and z03). Data represent the mean ± SD (n = 192). (c) Slope values obtained from raw fluorescence data for the three replicate 
plates (b) showing stable fluorescence in both controls. The mean slope values between negative and positive control are significantly 
different (analysis of variance, p < .001)
PI range (%) ≤30 31–40 41–50 51–60 61–70 71–80 81–90 91–100
No. of compounds 6,511 35 21 20 9 6 6 12
TA B L E  2   Percentage of inhibition (PI) 
of assayed compounds
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been to select resistant sweet potato genotypes (Tairo et al., 2005; 
Ngailo et al., 2019). However, there are few sweet potato cultivars 
resistant to sweet potato virus disease in the field, especially in East 
Africa where there is a great demand for virus-resistant sweet po-
tatoes for subsistence farming. Additionally, resistance observed 
under experimental conditions may not be reproducible in the field 
F I G U R E  6   Structures of the compounds with percentage of inhibition (PI) > 90% in the primary screen. The black stars indicate the top 
three compounds identified by the dose–response screen
Compound ID FIMM027745 FIMM072577 FIMM031755
DSS 19.2 18.3 15.9
IC50 647.4 nM 699.3 nM 1,268.9 nM
Dose–response curves
TA B L E  3   The top three most potent inhibitors of CSR3 as determined with the dose–response assay based on drug-sensitivity score 
(DSS) values
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(Okada et al., 2017). It has been documented that CSR3 of SPCSV 
targets the host plant's RNAi system to cripple the antiviral defence 
system and increase sweet potato sensitivity to other RNA viruses. 
Because there is no effective means of counteracting sweet potato 
virus disease at present, we believe that the identification of an in-
hibitor of this harmful RNAi suppressor would open the way for new 
antiviral strategies for sweet potato. Hence, we carried out a small-
molecule screening project targeting CSR3.
Class 1 RNase III enzymes such as CSR3 only contain an RNA-
binding domain and a catalytic domain, whereas other classes of 
RNase III enzymes such as Drosha and Dicer have more complex 
structures, with several domains, allowing the processing of mi-
croRNAs of different lengths (Court et al., 2013; Liang et al., 2014; 
Nicholson, 2014). Thus, it was expected that the class 1 RNase III 
enzymes would not have any size selectivity in vitro and can pro-
cess any size of dsRNA. In addition, because the amino acid iden-
tity between CSR3 and Ipomoea endogenous RNase III is very low 
(<5%), we believe there is a high probability of identifying CSR3-
specific inhibitors. We selected a 22 bp siRNA with a two-nucleotide 
overhang along with a specific FRET reporter (FAM) and quencher 
(BHQ1) for four main reasons. First, studies have shown that small 
RNA duplexes are properly processed by CSR3 (Weinheimer et al., 
2014). Second, eukaryotic siRNAs have both a structure and size 
that are typical of viral siRNAs (21–24 bp with a two-nucleotide 
overhang). Third, and most importantly, this size is within the range 
of the Förster interaction radius, allowing use in FRET-based HTS. 
Finally, the fluorescence spectrum of 485/520 nm used in this assay 
is common in commercially available fluorometers. Moreover, in the 
HTS assay, to avoid false-positive results caused by the degradation 
or disassembly of two strands of the siRNAs substrate, both reporter 
and quencher were fused on the sense siRNA strand. Thus, the FRET 
signal could only be induced when siRNA was cleaved by CSR3. 
Based on this, the identified potential inhibitors could bind within 
the active site of RNase III or bind to a specific location essential for 
siRNA loading into CSR3.
FRET is a distance-sensitive method requiring a Förster in-
teraction radius of less than 10 nm (Piston and Kremers, 2007). 
FRET has been commonly used with 20- to 25-nucleotide-long 
labelled oligonucleotide probes (Didenko, 2001; Ram et al., 2008). 
Moreover, FRET-based methods allow measurements of fluores-
cence changes in real time because the FRET signal decays expo-
nentially in nanoseconds without excitation (Piston and Kremers, 
2007). To use FRET in HTS, reproducibility is an important factor 
owing to the rate of FRET decay, which is highly sensitive to ex-
perimental factors such as pH, buffer reagents, and fluorescence 
quenchers (Piston and Kremers, 2007). To ensure the assay per-
formed well and consistently within and between plates, we car-
ried out a three-plate test with only negative and positive controls. 
This test was necessary because small molecules are usually tested 
at a single concentration for primary-inhibitor HTS (Ahsen and 
Bomer, 2005; Campagnola et al., 2011; Ilouga and Hesterkamp, 
2012). We report here an HTS assay of 6,620 compounds cher-
ry-picked from different compound libraries provided by the 
Institute for Molecular Medicine Finland (FIMM). The HTS screen-
ing was carried out for 7 hr using 384-well plates and a 20 µl vol-
ume. Considering the sensitivity of the FRET-based assay, it could 
be possible to use the 1,536-well format and miniaturize the assay 
to 1–5 µl per well (Rodems et al., 2002). Therefore, our method 
could be easily adapted to screen larger compound libraries to 
identify potential new drugs. On the contrary, detection time is 
influenced by many factors, for example the ratio of the concen-
tration of the enzyme to substrate, reaction buffer, and reaction 
conditions. In our primary assays, measuring kinetics for eight cy-
cles (11 min total) was sufficient for obtaining good results, yet, 
we monitored the reaction for 12 cycles (17 min total) to obtain 
more consistent results. It is noteworthy that the measurement 
F I G U R E  7   Comparison of percentage 
of inhibition (PI) values between CSR3 
and EcR3. The PI values of 109 individual 
compounds for CSR3 of SPCSV (CSR3, 
light yellow dots) differed significantly 
(analysis of variance, p < .001) from those 
for RNase III of Escherichia coli (EcR3, light 
blue dots). The average PI value for CSR3 
was 54.4% (light yellow dashed line), and 
that for EcR3 was 17.1% (light blue line)
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time cannot be less than 4 min because of the high variability in 
reaction kinetics caused by heating the plate while acquiring re-
sults. We recommend monitoring the HTS assay for ≥10 min for 
the purpose of identifying RNase III inhibitors. Moreover, we tried 
to carry out HTS at c.25 °C, but the catalytic efficiency was rather 
low, and therefore HTS assay required more enzyme or time to 
achieve similar results than the recommended 37 °C condition.
We identified 109 CSR3 inhibitors in the assays with a PI value 
of 30% as a threshold. By raising the threshold, one is able to ef-
fectively reduce the number of potential false-positives, and induce 
false-negatives (Ilouga and Hesterkamp, 2012). The best three com-
pounds (FIMM027745, FIMM072577, and FIMM031755), accord-
ing to their DSS in the dose–response screening of CSR3, were all 
synthetic compounds. Moreover, all three compounds have not 
been reported as effective drugs according to Drugbank (https://
www.drugb ank.ca/). However, according to PubChem database, 
FIMM031755 (CID: 7,114,450) has been involved in an inhibitor 
screening assay for Cytokine/receptor Binary Complex of humans 
(4KC3_B) and was shown to be effective at micromolar concentra-
tions. FIMM027745 (CID: 712,810) has been used in several inhibi-
tor screens, for example HIV-1 reverse transcriptase and human heat 
shock 70 kDa protein, but was inactive in all studies.
In the future, the promising candidates could be transferred 
to plants. Two compounds were tested at several concentrations 
(0.1 nM to 100 µM) on sweet potato plants coinfected with both 
SPCSV and SPFMV grown in medium. Preliminary results of the two 
compounds FIMM027749 and FIMM072436 with different PI val-
ues (88% and 41%, respectively) showed that FIMM027749 was able 
to down-regulate virus accumulation of both SPCSV and SPFMV by 
two to three times, but without displaying a typical dose–response 
curve (Figure S2a,b). Compound FIMM072436, on the other hand, 
had a mild impact on SPFMV but no impact on SPCSV (Figure S2a,b). 
Their effects on virus accumulation in plants were consistent with 
the PI values obtained by in vitro assay. At the same time, plant 
height over time was estimated and both compounds did not have 
any effect on plant growth (see plant picture in Figure S2c), suggest-
ing that they did not interfere with plant development through non-
specific interaction with host factors including endogenous RNase 
III. Therefore, the chance of identifying inhibitors that could work in 
vivo should be high. Nonetheless, these data are still preliminary and 
more in vivo assays or biochemistry tests will be needed to develop 
the candidates as antiviral agents in the future.
The identification in a fish DNA virus, Pike-perch iridovirus, 
of an RNase III protein with a similar RNAi suppression function 
(Weinheimer et al., 2015) indicates that RNase III-based viral sup-
pression exists in both plant RNA virus (SPCSV) and animal DNA 
virus (Pike-perch iridovirus), thus it is likely that more viral RNase III 
acting as RSSs are present in nature waiting for discovery. In addi-
tion, our HTS assay was also successfully applied to the screening of 
bacterial EcR3, validating that this assay could be adapted to other 
similar RNase IIIs. Moreover, the different screening results between 
CSR3 to EcR3 demonstrate not only the specificity of the screen-
ing method but also the possibility of identifying broad-spectrum 
inhibitors for class 1 RNase III. Taken together, our findings provide 
possibilities for developing new antiviral strategies for sweet potato 
virus disease, and our HTS assay could be used to identify inhibitors 
of various class 1 RNase III enzymes.
4  | E XPERIMENTAL PROCEDURES
4.1 | Protein expression and purification
C-terminal His-tagged CSR3 (GenBank ADQ42569.1) and CSR3-A 
(D37A, D44A) were expressed in E. coli from the plasmid pET11d 
(Kreuze et al., 2005; Weinheimer et al., 2015). Bacterial cultures 
were grown under selection with ampicillin (100 µg/ml) and chlo-
ramphenicol (25 µg/ml) at 37 °C for 2 hr. Recombinant proteins 
were induced by adding 0.1 mM (final concentration) of isopropyl 
β-d-1-thiogalactopyranoside into the culture medium and grow-
ing for 4 hr. Bacterial cells were lysed in lysis buffer (10 mM imi-
dazole) supplemented with a tablet of protease inhibitor cocktail 
(cOmplete ULTAR Tablets, mini, Roche) per 10 ml lysis buffer and 
1 mg/ml lysozyme (Sigma-Aldrich) while incubating for 2 hr on ice. 
Sonication (50% duty cycle, 4 × 15 s; Branson Sonifier [B15OR Cell 
Disruptor B15]) was used to additionally disrupt cells and degrade 
nucleic acids.
Ni-NTA agarose gravity-flow chromatography (Qiagen) was 
used to purify His-tagged proteins. Bacterial extract was loaded 
onto polypropylene columns (Qiagen) and washed successively with 
wash buffer 1 (50 mM imidazole) and wash buffer 2 (70 mM imid-
azole). Bound proteins were eluted with elution buffer (500 mM 
imidazole). Lysis buffer, wash buffer, and elution buffer were made 
using the His Buffer kit from GE Healthcare. Fractions containing 
high concentrations of pure protein were collected, subjected to 
buffer exchange with a PD MidiTrap G-25 (GE Healthcare), and 
finally diluted in storage buffer (20 mM MgCl2, 40 mM Tris-HCl, 
100 mM NaCl, pH 8.0, 5% glycerol). The Bradford colorimetric 
method (Protein Assay, Dye Reagent concentrate, Bio-Rad) and a 
NanoDrop spectrophotometer (Thermo Fisher Scientific; 280 nm) 
were used for protein quantification. Coomassie Brilliant Blue re-
agent [10% (vol/vol) glacial acetic acid, 40% (vol/vol) methanol, 1% 
(wt/vol) Coomassie Brilliant Blue G] was used to visualize proteins 
in gels following SDS-PAGE.
4.2 | CSR3 activity assay as assessed with agarose 
gel electrophoresis
The dsRNA molecules (200 bp) were generated using the 
TranscriptAid T7 High-Yield Transcription kit (Thermo Fisher 
Scientific). To precipitate dsRNA, samples were incubated with 
2.5 M ammonium acetate on ice for 15 min and centrifuged at 
10,000 × g for 15 min at 4 °C. After removing the supernatant, the 
pellet was washed twice with 70% ethanol, air-dried at room tem-
perature for 10 min, and resuspended in RNase-free water (50 µl). To 
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reanneal RNA as a double strand, samples were incubated at 95 °C 
for 10 min, 65 °C for 1 min, and room temperature before storage 
at −20 °C. RNase activity was tested in 20 µl reactions (20 mM Tris-
HCl, 50 mM NaCl, 10 mM MgCl2, pH 8) containing 300 ng of 200-bp 
dsRNA and 200 ng enzyme. Each reaction was incubated for 40 min 
at 37 °C before loading on a 1% agarose gel.
4.3 | Western blotting
Proteins were resolved via Tris-glycine SDS-PAGE (12% polyacryla-
mide) and transferred to polyvinylidene difluoride membrane (GE 
Healthcare) by electroblotting. After SDS-PAGE electroblotting, gels 
were stained with Coomassie Brilliant Blue to confirm that the major-
ity of proteins were transferred. Each membrane was then incubated 
for 60 min in phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 8) containing 0.1% (wt/
vol) Tween-20 (PBS-Tween) with 5% non-fat dried milk and washed 
3 × 10 min in TBS-Tween at room temperature. Then, each mem-
brane was incubated for 1 hr with a CSR3-specific rabbit polyclonal 
antibody (Kreuze et al., 2005) diluted 1:1,000 in PBS-Tween contain-
ing 2.5% dried milk. After three washes with PBS-Tween, each mem-
brane was soaked for 1 hr with horseradish peroxidase-conjugated 
anti-rabbit IgG (Sigma-Aldrich) diluted 1:5,000, and bands were 
visualized with the West Pico chemiluminescence development sub-
strate (Thermo Fisher Scientific). Chemiluminescence was detected 
with X-ray film (Roche) using an enhanced chemiluminescence kit 
from GE Healthcare.
4.4 | Size-exclusion chromatography coupled with 
multi-angle light scattering
Size-exclusion chromatography coupled with multi-angle light 
scattering was used for characterizing oligomeric states of CSR3. 
Samples of purified recombinant CSR3 diluted in PBS were loaded 
onto a Superdex S-200 10/300 GL (GE Healthcare) column at 0.5 ml/
min with an HPLC system (Shimadzu) coupled with MiniDAWN 
TREOS multi-angle light-scattering detector, and Optilab rEX refrac-
tive index detector (Wyatt Technology). The injection volume was 
100 µl per sample, and chromatography was carried out at 4 °C. The 
concentration of protein in the effluent was measured with a light-
scattering detector (493-TS; RI instrument 686-REX, 658 nm; UV in-
strument SPD-M20A). Data were analysed with ASTRA 6 software 
(Wyatt Technology).
4.5 | Labelled siRNA constructs
A two-nucleotide, 3′-overhang siRNA of 22 bp labelled with 
a FAM reporter and BHQ1 quencher (forward: 5′-FAM-
CGUAGUGGAAGUGGGAGAGGTC-BHQ1-3′; reverse: 5′-CCUCUC 
CCACUUCCACUACGTG-3′) were synthesized by Metabion. Their 
identity and purity were verified by HPLC. The RNA oligonucleotides 
were dissolved in annealing buffer (6 mM PIPES pH 7.5, containing 
60 mM KCl and 0.2 mM MgCl2) at a concentration of 100 µM, ali-
quoted in volumes ranging from 10 to 200 µl and stored at −20 °C. 
Before use, siRNA was diluted to 15 µM (200 ng/µl) with annealing 
buffer, incubated for 2 min at 93 °C, and cooled to room temperature 
(≥30 min).
4.6 | FRET assay development
The HTS assay was designed to maximize siRNA cleavage by CSR3. 
We used a donor–quencher fluorogenic siRNA as the substrate 
for CSR3. To optimize the enzyme:substrate ratio, a CSR3 titra-
tion assay was carried out by mixing six different concentrations 
of CSR3 (0–1150 nM) with 375 nM labelled siRNA according to 
results obtained from a preliminary test. To assess CSR3 activity, 
five labelled siRNA concentrations (50–800 nM) were used with 
50 nM CSR3. To test the reproducibility and precision of the assay, 
full plates containing only negative (50 nM CSR3) and positive re-
actions (lacking CSR3) were tested with 375 nM labelled siRNA. 
Enzyme and substrate were prepared separately at 2 × final con-
centration, and then 10 µl of each was dispensed into every well 
with an automated dispenser (MultiFlo FX with single-channel 
RAD-cassettes; BioTek). Plates were 384-well black flat-bottomed 
microplates (#3544, Corning).
4.7 | HTS assay
For the HTS assay, plates (10 µM compound in each well) were 
prepared with an Echo liquid handler (Labcyte) at the FIMM 
(Institute for Molecular Medicine Finland) High-Throughput 
Biomedicine unit. CSR3 and annealed siRNA were diluted to 
200 and 750 nM, respectively, in reaction buffer (50 mM Tris-
HCl, 125 mM NaCl, 25 mM MgCl2, pH 8.0). CSR3 solutions were 
dispensed into the wells of plates (10 µl CSR3 per well). Plates 
were incubated at room temperature for 15 min with shaking 
(450 rpm). Subsequently, 10 µl substrate was dispensed per 
well. The final CSR3 and substrate concentrations were 100 and 
375 nM, respectively. The dose–response assay with six com-
pound concentrations (range, 1.25 nM to 50 µM) was carried out 
with the same conditions. Plates were sealed, centrifuged briefly, 
and then, immediately analysed with a PHERAstar FS (BMG 
Labtech) with a fluorescence-intensity optic module (excitation 
at 485 ± 6 nm, detection at 520 ± 5 nm) for 12 cycles (c.17 min 
total) at 37 °C. All dispensing was done using the BioTek MultiFlo 
FX. All screening plates contained positive-control wells (lack-
ing CSR3) and negative-control wells (25 nl dimethyl sulphox-
ide, vehicle), which were used as standards to calculate the PI of 
compounds.
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4.8 | Data analysis
The endoribonuclease activity of CSR3 was calculated with slope, 
representing fluorescence changes in function of assay time (s), 
using MARS Data Analysis software (BMG Labtech). In addi-
tion, the Z′ of the assay was calculated according to Equation 1 
(Zhang et al., 1999), which was used to evaluate the suitability of 
the method during assay development, optimization, and screen-
ing. Moreover, the signal-to-noise ratio and signal-to-background 





∕휎c+ and the signal-to-background 
ratio = 휇c−∕휇c+.
where μc+ is the mean of the positive control, μc− is the mean of the 
negative control, σc+ is the standard deviation of positive control, and 
σc− is the standard deviation of the negative control.
The PI of each compound for CSR3 was calculated according to 
Equation 2. A PI threshold of 30% was used as the cut-off value for 
one concentration of HTS. Furthermore, the dose–response curves 
of PI in function of compound concentration were evaluated with 
DSS according to Yadav et al. (2014).
where Sc+ is the mean of the slope of the positive control, Sc− is the 
mean of the slope of the negative control, and Ss is the mean of the 
slope of samples.
The kinetic constant (Kd) for CSR3 was calculated using the 
three-parameter Michaelis–Menten model (MM.3) included in the R 
package dcr (Ritz et al., 2015). The statistical significance of differ-
ences between values was assessed with one-way ANOVA using the 
aov function in the R package.
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